News

In this article, Dr. Paul Quigley, Quotient Sciences' Principal Research Fellow of Drug Substance discusses the need to reduce white space in the oncology drug development process. White space where Quotient Sciences’ integrated Translational Pharmaceutics platform is uniquely positioned to help.

Quotient Sciences, a leading global pharmaceutical drug development and manufacturing accelerator, is proud to announce the successful completion of a US Food and Drug Administration (FDA) inspection of its bioanalytical facility in Alnwick, UK.

Drug product optimization, also known as reformulation, is a development step required by all drugs en route to market. John McDermott, VP of Scientific Consulting at Quotient Sciences featured in a new 'Innovations in Pharmaceutical Technology' article.

Dr. Paul Quigley, our Principal Research Fellow, Drug Substance, suggests that the nature of new molecular entities (NMEs) and new modalities are rapidly changing in a Manufacturing Chemist feature.

Catherine Wilkes, Executive Director of Environmental, Health and Safety at Quotient Sciences featured in European Pharmaceutical Manufacturer explores how containment protocols shift when dealing with HPAPIs to meet the required safety standards.

Contract Pharma's latest article on HPAPI manufacturing trends features Quotient Sciences' Director of Drug Development Consulting, Stephen McQuaker, who discusses the development of early-stage new chemical entity (NCE) drug candidates.